ICU Medical, Inc. ICUI

Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during risk-on environments, many also struggle to maintain investor confidence when the ride gets bumpy.

ICU Medical has climbed back into positive territory over the past year, yet its longer track record remains mixed, which puts fresh attention on what the current share price asks you to pay for its future cash flows. With the stock closing at US$152.65 most recently, the key issue is whether that tag lines up with what the business can realistically generate over time. Over the past 5 years, ICU Medical shares have fallen 37.1%, which makes the current valuation question more about the...

The global vascular access device market is projected to grow from USD 6.27 billion in 2026 to USD 8.68 billion by 2031, at a 6.7% CAGR. Growth is driven by rising cancer, cardiovascular and kidney disease cases, increased IV therapies and advances in safety-engineered, antimicrobial and ultrasound-guided devices. Peripheral devices and drug administration will see strong growth, while clinics and ambulatory care centers gain adoption. Asia Pacific is forecast to record the highest CAGR. Key pla

The sale was part of a trading plan established in June.

Bonnell retains 62,443 direct shares.

Baxter raises its 2026 sales and earnings outlook after strong Q2 growth, though manufacturing costs, tariffs and pricing pressure margins.

Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Drug Reconstitution Systems Market - Trends and Forecast Till 2035" has been added to ResearchAndMarkets.com's offering. The global drug reconstitution systems market is projected to increase from approximately USD 5.9 billion in 2026 to USD 10.8 billion by 2035, representing a compound annual growth rate (CAGR) of about 7.0% during the forecast period. Market expansion is being supported by the growing pipeline of biologics, biosimilars, vaccines,

SAN CLEMENTE, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq: ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced its participation in the following investor conferences: Wells Fargo 21st Annual Healthcare Conference on September 9-10, 2026 Company management will attend the Wells Fargo 21st Annual Healthcare Conference, held at the Encore Boston Harbor in Boston, MA, participating in one-on-one meetings on Wednesday, Sept

Let’s dig into the relative performance of ICU Medical (NASDAQ:ICUI) and its peers as we unravel the now-completed Q2 medical devices & supplies - cardiology, neurology, vascular earnings season.

Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside risk because they lack the scale and staying power of their larger competitors.

ICU Medical has had an impressive run over the past six months as its shares have beaten the S&P 500 by 9.3%. The stock now trades at $182.79, marking a 23.3% gain. This was partly due to its solid quarterly results, and the run-up might have investors contemplating their next move.

ICU Medical’s second quarter results were well received by the market, with management highlighting robust performance in the Infusion Systems and Consumables segments as key drivers. CEO Vivek Jain emphasized that North America led growth, and noted that “record quarters” in both pumps and consumables reflected broad-based demand and incremental wins. Operational efficiencies stemming from IT system integration and facility consolidation also contributed to improved operating margins. Managemen

The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher volatility and risk, as their smaller size makes them more vulnerable to economic downturns.

Infusion Systems revenue hit record highs with 12% organic growth and strong pump sales.

Medical device company ICU Medical (NASDAQ:ICUI) reported Q2 CY2026 results beating Wall Street’s revenue expectations, but sales were flat year on year at $547.9 million. Its non-GAAP profit of $2.37 per share was 23.8% above analysts’ consensus estimates.

Shares of medical device company ICU Medical (NASDAQ:ICUI) jumped 10.2% in the afternoon session after the company posted strong second-quarter results that surpassed Wall Street expectations and raised its full-year earnings forecast.

ICU Medical has seen its analyst fair value move from US$172.50 to US$191.50, which places the stock closer to the US$200 price targets now appearing in recent research. Bullish analysts connect this higher fair value to execution on pump driven growth, improving margins, and progress on free cash flow, as reflected in several target hikes and a rating upgrade since early 2025. Read on to see how this evolving narrative might matter for your view on ICU Medical and how to track the next set...

Moby summary of ICU Medical, Inc.'s Q2 2026 earnings call